Modality
Small Molecule
MOA
IL-13i
Target
CD20
Pathway
Sphingolipid
AngelmanWMMeso
Development Pipeline
Preclinical
~Nov 2016
→ ~Feb 2018
Phase 1
~May 2018
→ ~Aug 2019
Phase 2
~Nov 2019
→ ~Feb 2021
Phase 3
~May 2021
→ ~Aug 2022
NDA/BLA
Nov 2022
→ Apr 2025
NDA/BLACurrent
NCT03361133
1,843 pts·WM
2022-11→2025-04·Active
1,843 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-04-2511mo agoPh3 Readout· WM
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2
NDA/BLA
Active
Catalysts
Ph3 Readout
2025-04-25 · 11mo ago
WM
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03361133 | NDA/BLA | WM | Active | 1843 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| Lisolucimab | Novartis | Approved | CD20 | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 |